Silence Therapeutics (SLN)

Executive Summary

Silence Therapeutics is a publicly traded biotechnology company pioneering siRNA-based therapeutics to address diseases with limited treatment options. Founded in 1994 and headquartered in London, the company leverages its proprietary siRNA platform to develop precision-engineered medicines. Its pipeline includes SLN124, a GalNAc-conjugated siRNA targeting TMPRSS6 for iron overload disorders such as non-transfusion-dependent thalassemia and polycythemia vera (PV), currently in a Phase 1/2 trial. Additionally, SLN360 targets lipoprotein(a) (Lp(a)) for cardiovascular disease, having completed Phase 2. The company also has earlier-stage assets like Atu027 for solid tumors, though these are less advanced. Recent developments include the completion of SLN360’s Phase 2 study in Lp(a) and ongoing enrollment for SLN124 in PV. The company holds a market valuation of approximately $330 million and is well-positioned to deliver near-term catalysts, including potential Phase 2 data readouts and partnership opportunities around its siRNA platform. While no products are yet commercialized, Silence’s robust pipeline and novel technology provide a foundation for future growth, though execution risk remains given the early stage of key programs.

Upcoming Catalysts (preview)

• H2 2026SLN124 Phase 1/2 interim data in Polycythemia Vera50% success
• H2 2026Presentation of SLN360 Phase 2 results in Lp(a) at a medical conference70% success
• 2026Potential partnership or licensing deal for siRNA platform30% success